Drugs / iSCIB1+
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04079166 | Aug 2019 → Jan 2027 expected | cutaneous melanoma | Scancell Ltd | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iSCIB1+ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04079166 ↗ |
| Modality | Vaccine | “SCIB1 or iSCIB1+ DNA vaccine” NCT04079166 ↗ |
| Route | Other | “The SCIB1 or iSCIB1+ injection will be given using PharmaJet needle-free injection device systems in the upper arm or upper leg.” NCT04079166 ↗ |